Implanet SA : Implanet reports 2016 sales growth of +18 pct to 7.8 million euros ($8.3 million) .FY sales 7.8 million euros versus 6.7 million euros year ago.
Essilor /Luxottica : Transaction would entail Delfin contributing its entire stake in Luxottica (approx. 62%) to Essilor in return for newly-issued Essilor shares to be approved by the Essilor shareholders meeting, on the basis of the exchange ratio of 0.461 Essilor shares for 1 Luxottica share . Essilor subsequently making a mandatory public exchange offer, in accordance with the provisions of Italian law, to acquire all of the remaining issued and outstanding shares of Luxottica pursuant to the same exchange ratio and with a view to delist Luxottica's shares . Essilor would become a holding company with the new name "EssilorLuxottica" via a hive-down of all of its operating activities into a wholly-owned company, to be called Essilor international, and the contribution by Delfin of its Luxottica shares . Following the transaction, Delfin would own between 31% and 38% of the shares of EssilorLuxottica and would be its largest shareholder Further company coverage: [ESSI.PA] ((firstname.lastname@example.org;)).
Pixium Vision SA :Pixium vision achieves implantation of 10 patients in its clinical trial with its innovative 150 electrodes Iris II bionic vision system.
Medicrea International SA :Q4 sales rose 13 percent to 7.8 million euros.